Characterization of cellular immune responses in Thai individuals with and without HIV-associated neurocognitive disorders

Tanate Jadwattanakul
Washington University School of Medicine in St. Louis
Short Communication: Characterization of Cellular Immune Responses in Thai Individuals With and Without HIV-Associated Neurocognitive Disorders

Silvia Ratto-Kim1,2,* Alexandra Schuetz1,3,* Pasiri Sithinamsuwan4, John Barber5, Nicholas Hutchings6, Sukalaya Lerdlum7, James L. K. Fletcher8, Yuwadee Phuang-Ngern3, Weerawan Chuenarom3, Sompon Tipsuk8, Mantana Pothisri7, Tanate Jadwattanakul6, Supunnee Jirajariyavej10, Chayada Sajjaweerawan3, Siriwat Akapirat3, Thep Chalermchai8, Duangthai Suttichom8, Boot Kaewboon3, Peeriya Pruksaew8, Putthachard Karnsomlap8, David Clifford1, Robert H. Paul11, Mark S. de Souza8, Jerome H. Kim12, Jintanat Ananworanich1,2,8, and Victor Valcour13; on behalf of the SEARCH 007 Study Group

Abstract

HIV-associated neurocognitive disorder (HAND) remains a challenge despite antiretroviral therapy (ART), and has been linked to monocyte/macrophage (M/M) migration to the brain. Due to the potential impact of T cell effector mechanisms in eliminating activated/HIV-infected M/M, T cell activation may play a role in the development of HAND. We sought to investigate the relationship between cognition and both CD8+ T cell activation (HLA-DR+/CD38+) and HIV-specific CD8+ T cell responses at the time of HIV diagnosis and 12 months postinitiation of ART. CD8+ T cell activation was increased in HAND compared to cognitive normal (NL) individuals and correlated directly with plasma viral load and inversely with the cognitive status. In addition, Gag-specific cytolytic activity (CD107a/b+) was decreased in HAND compared with NL individuals and correlated with their neurological testing, suggesting a potential role of cytotoxic CD8+ T cells in the mechanism of HAND development.

Keywords: HIV-associated neurocognitive disorders, CD8+ T cell activation, HIV-specific cytolytic T cells

Antiretroviral therapy (ART) has greatly reduced the incidence of the most severe forms of HIV-associated neurocognitive disorders (HAND), but milder forms of impairment remain common. Investigations of HAND have largely focused on monocytes/macrophages (Ms/Ms) due to their susceptibility to infection and ability to cross the blood–brain barrier once activated.1 Peripheral measures of M/M frequency correlate with HAND symptoms and are predictive of central nervous system (CNS) dysfunction in nonhuman primates, leading many to conclude that M/M are critically involved in CNS pathogenesis.2 M/M take their functional cues, in part, from the cognate system, which is highly disrupted during chronic HIV infection. Consequently, it can be hypothesized that T cells...
could play a larger role in CNS pathogenesis and protection.\textsuperscript{3} CD8\textsuperscript{+} T cell activation is associated with early neuronal changes and strongly correlates with cerebrospinal fluid (CSF) viral load in macaques that develop encephalitis later during infection.\textsuperscript{4} More importantly, the depletion of CD8\textsuperscript{+} T cells leads to more rapid progression of SIV-associated encephalitis.\textsuperscript{5} Their inability to kill HIV-infected target cells may lead to the unchecked transmigration of activated M/M to the brain.

Although, CD8\textsuperscript{+} T cell frequency and functionality have been associated with better overall clinical outcomes, their impairment has not been specifically linked to the development of HAND. Hence, we hypothesized that impaired cognate CD8\textsuperscript{+} T cell responses may be involved in cognitive impairment. In this study, we assessed the frequency of activated CD8\textsuperscript{+} T cells and HIV-specific CD8\textsuperscript{+} T cell response in HAND versus cognitively normal (NL) individuals at the time of HIV diagnosis and 12 months post-ART initiation.

Fifty ART-naive HIV-infected volunteers (CD4 count <350 cells/mm\textsuperscript{3}) were enrolled into the SEARCH 007 study (NCT00777426) at the Thai Red Cross AIDS Research Centre in Bangkok, Thailand. Hepatitis C infection and illicit drug use within the past 5 years as well as a positive illicit drug screen were exclusion criteria (further information can be found under clinicaltrials.gov). Based on clinical assessment and neuropsychological testing battery, 23/50 were characterized as cognitively normal (NL), and 27/50 with symptomatic HAND (CD8\textsuperscript{+} T cell activation is associated with early neuronal damage and pathogenesis and protection).\textsuperscript{3} Their inability to kill HIV-infected target cells may lead to the unchecked transmigration of activated M/M to the brain.

At the time of HIV diagnosis, NL and HAND individuals showed a significantly higher frequency of activated CD8\textsuperscript{+} T cells, indicated by the expression of HLA-DR and CD38 (CD8\textsuperscript{+}DR\textsuperscript{+}CD38\textsuperscript{+}), compared to CO (NL 26.4% and HAND 41.8% vs. CO 2.8%; \(p<.001\), which remained elevated at 12 months post-ART initiation (NL 7.2% and HAND 14.6% vs. CO 2.8%; \(p<.001\), Fig. 1A). However, we observed a significant decrease in the frequency of CD8\textsuperscript{+}DR\textsuperscript{+}CD38\textsuperscript{+} T cells in both NL and HAND individuals between time of diagnosis and 12 months post-ART initiation from 26.4% to 7.2% and 41.8% to 14.6% (\(p<.001\), respectively). The frequency of CD8\textsuperscript{+}DR\textsuperscript{+}CD38\textsuperscript{+} T cells in HAND individuals was higher compared with NL individuals at both time points (baseline: NL 26.4% vs. HAND 41.8%; 12 months post-ART: NL 7.2% vs. HAND 14.6%), however, not statistically significant.

Similar trends were observed for CD4\textsuperscript{+}DR\textsuperscript{+}CD38\textsuperscript{+} T cells, where the frequencies of CD8\textsuperscript{+} T cell responses were significantly higher in NL compared with HAND (\(p<.001\); data not shown).

During ART initiation NL showed a median CD4 count of 393 cells/mm\textsuperscript{3} (IQR 249–548) and HAND individuals of 356 cells/mm\textsuperscript{3} (IQR 212–516; \(p=.34\); Supplementary Table S1; Supplementary Data are available online at www.liebertpub.com/aid). In addition, 10 matched HIV-seronegative healthy individuals (CO) were enrolled (age range 24–46 years). Earlier, written signed informed consent was obtained from all participants.

Frozen peripheral blood mononuclear cells (PBMCs) were thawed and 1 × 10\textsuperscript{6} PBMC were used for phenotypical flow-cytometric assessment and in a standard intracellular cytokine staining (ICS) assay for antigen-specific T cells as previously described.\textsuperscript{7} PBMC were stained with Aqua Live/Dead (Invitrogen) and the following antibodies: anti-CD3-PE-Cy7 (Invitrogen), anti-CD4-ECD (Beckman Coulter), anti-CD8-PerCP-Cy5.5, anti-HLA-DR-V450 and anti-CD38-APC (BD Bioscience), anti-CD107a/b-FITC, anti-CD14-AF700, anti-CD19-AF700 (BD Pharmingen), and anti-IFN-\gamma-Pacific Blue (eBioscience). Cells were acquired using a custom-build LSRII flowcytometer (BD Bioscience) and analyzed using FlowJo (version 9.8 or higher; Tree Star; Supplementary Fig. S1). A median of 99,800 (range 16,800–163,000) CD3\textsuperscript{+} lymphocytes were acquired. A positive ICS response was defined as at least 3 × background control and \(\geq 20.05\%\) gated positive cells. GraphPad Prism Version 6.0 or higher was used for statistical analysis and presentation. Statistical comparison between groups was performed using the Mann–Whitney test and a Wilcoxon test for matched samples, with \(p\)-values \(\leq .05\) considered significant. For correlation analysis, the Spearman rank test was used, and for the effect size, a Cohen’s \(d\) test was used.

The frequency of CD8\textsuperscript{+} T cell expression in both NL and HAND individuals was not related to CD4 count at the time of diagnosis or at 12 months post-ART initiation (\(p>.05\), respectively; data not shown). The frequency of CD8\textsuperscript{+}DR\textsuperscript{+}CD38\textsuperscript{+} T cells was significantly higher in NL compared with HAND (\(p<.001\); data not shown). The frequency of CD8\textsuperscript{+}DR\textsuperscript{+}CD38\textsuperscript{+} T cells in HAND individuals was higher compared with NL individuals at both time points (baseline: NL 26.4% vs. HAND 41.8%; 12 months post-ART: NL 7.2% vs. HAND 14.6%), however, not statistically significant.

The frequency of CD8\textsuperscript{+}DR\textsuperscript{+}CD38\textsuperscript{+} T cells in HAND individuals was significantly lower than in NL individuals at both time points (baseline: NL 26.4% vs. HAND 41.8%; 12 months post-ART: NL 7.2% vs. HAND 14.6%), however, not statistically significant.

The frequency of CD8\textsuperscript{+}DR\textsuperscript{+}CD38\textsuperscript{+} T cells in HAND individuals was significantly lower than in NL individuals at both time points (baseline: NL 26.4% vs. HAND 41.8%; 12 months post-ART: NL 7.2% vs. HAND 14.6%), however, not statistically significant.
FIG. 1. Characterization of CD4+ and CD8+ T cells among NL and HAND individuals at the time of HIV diagnosis and 12 months post-ART initiation. (A) Coexpression activation markers HLA-DR and CD38 on CD8+ T cells and (B) on CD4+ T cells in NL (light gray symbols) and HAND (dark gray symbols) individual, and in healthy controls (red dotted line), as the time of diagnosis and 12 months post-ART initiation. (C) Correlation of CD8+ HLA-DR+CD38+ T cells with plasma viral load and (D) with NPZ-score at the time of HIV diagnosis and 12 months post-ART initiation. (E) Frequency and number of individuals with CD107a/b- and (F) IFN-γ-expressing Gag-specific CD8+ T cells among NL and HAND individuals at the time of HIV diagnosis and 12 months post-ART initiation. (G) Correlation of the frequency of Gag-specific CD107a/b-expressing CD8+ T cells with the NPZ-score at the time of diagnosis. (H) Correlation of the frequency of Gag-specific CD107a/b-expressing CD8+ T cells at the time of diagnosis with the NPZ-score 12 months post-ART initiation.

Comparisons between groups (NL vs. HAND) were done using Mann–Whitney test, and comparison between matched samples within groups (baseline vs. 12 months) were done using Wilcoxon test. ART, antiretroviral therapy; HAND, HIV-associated neurocognitive disorder; NL, cognitively normal.
difference in the frequency of Gag-specific IFNγ-expressing CD8+ T cells between the two groups at time of diagnosis (0.7% vs. 0.3%, respectively; *p = .06) or 12 months post-ART initiation (0.2% vs. 0.1%, respectively; *p = .11; Fig. 1F). These findings are in accordance with observations showing lower frequencies of cytolytic CD8+ T cells compared with IFNγ-expressing T cells in the CSF, and partly in the periphery, of patients with HAND, suggesting failure of ART to suppress HIV replication in the CSF contributing to increased risk of HAND.8

Moreover, at the time of diagnosis the frequency of CD107a/b-expressing CD8+ T cells correlated with the NPZ-global score (*r = 0.31, *p = .05) indicating an impact of cytolytic CD8+ T cells in the development of cognitive impairment (Fig. 1G). In addition, the frequency of Gag-specific CD107a/b-expressing CD8+ T cells at the time of diagnosis correlated with the NPZ-score 12 months post-ART initiation (*r = 0.34, *p = .03; Fig. 1H). The statistical significance of the reported correlations is consistent with those observed by other studies between neurocognitive impairment and HIV disease biomarkers.9 However, 12 months following ART-initiation, a significant decrease in the frequency of CD107a/b- and IFNγ-expressing Gag-specific CD8+ T cells was observed compared to time of diagnosis in NL (CD107a/b: 0.9% vs. 0.4%, *p < .001, IFNγ: 0.7% vs. 0.2%, *p < .001) as well as in HAND individuals (CD107a/b: 0.4% vs. 0.1%, *p = .002, IFNγ: 0.3% vs. 0.1%, *p = .01; Fig. 1E, F), potentially due to reduction of pVLU upon ART initiation.

Although ART reduces the more severe forms of HAND, the etiology of mild to moderate cognitive impairment despite ART remains unclear but likely also involves mechanisms such as M/M infiltration/accumulation in the brain. There is growing evidence that multiple factors are involved in the development and persistence of cognitive dysfunction despite ART.1 A decreased CD4/CD8 ratio in both peripheral blood and the CSF strongly correlated with the grade of cognitive impairment in HIV patients on ART, highlighting the potential importance of T cells.10 In addition, the importance of cytolytic CD8+ T cells has been highlighted and their absence in the CSF potentially linked to the failure of ART to suppress HIV replication within the CNS.8

The aim of the present study was to evaluate the potential role of peripheral CD8+ T cells in the development of cognitive impairment. Our findings support a previous study10 showing a trend toward higher immune activation of CD8+ and CD4+ T cells in HAND compared with NL individuals. Activation status of CD8+, but not CD4+ T cells inversely correlated with cognitive status, which potentially could link ongoing immune activation and neurological injury. It is known, that ongoing immune activation is a strong predictor of HIV disease progression, but could also serve as a marker for the development of cognitive dysfunction.10

In addition, impairment of cytolytic CD8+ T cells has been shown to correlate with HIV disease progression.8,11 In vitro studies have demonstrated, that cytolytic CD8+ T cells both suppress and kill HIV replication in macrophages.12 We observed, that Gag-specific cytolytic CD8+ T cell responses (CD107a/b-expression) mounted in HAND individuals were significantly lower compared to NL individuals at the time of diagnosis and 12 months posttreatment, correlating with the NPZ-score. These findings suggest a more impaired cytolytic immune response in HAND individuals, which could contribute to a failure to prevent trafficking of activated/infected M/M to the brain and subsequently lead to the development of cognitive impairment. In contrast, there was no significant difference in the frequency of IFNγ-expressing CD8+ T cells observed between HAND and NL individuals at any time.

However, this was a relatively small, but well controlled, study, and hence, it was not within the scope of this study to address the full spectrum of relevant considerations such as the impact of early initiated ART on neurological impairment or interrogate T cell responses in the CSF. Consequently, further studies are necessary, that include a larger sample size to confirm and expand on those findings and to elucidate the level of CD8+ T cell impairment across compartments. Inclusion of exhaustion markers such as PD-1 or Tim-311 will also be valuable to determine whether these negative checkpoints moderate M/M trafficking into the brain.

Acknowledgments

We thank the study participants and staff from the Thai Red Cross AIDS Research Centre and Phramongkutklao Hospital, Department of Medicine in Bangkok for their valuable contributions to this study. SEARCH is a research collaboration between the Thai Red Cross AIDS Research Centre (TRCARC), the University of Hawaii and the Department of Retrovirology, U.S. Army Medical Component, Armed Forces Research Institute of Medical Sciences (AFRIMS). This work was supported by R01NS55359-2. The SEARCH 007 Study Group includes from SEARCH/TRCARC/HIV-NAT: Nipat Teeratakulpisarn, Somprarthana Rattanamanee, Sasiwimol Uboiyam, Tippawan Pankam, Supanit Pattanachaewit; from AFRIMS: Nantana Tantibul, Bessara Nuntapinit, Rapee Trichavaroj, Surat Jongsrakthaitae, Nipattra Tragonlugsana, Putida Saetun, Suchada Sukhumvittaya; from the U.S. Military HIV Research Program: Merlin Robb, Nelson Michael; from U.S. National Institutes of Allergy and Infectious Diseases: Irini Sereti; from University of California: Lauren Wendelken, Akash Desai, and Stephanie Chiao.

Disclaimer

Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense. Drs. Ananwonich and Valcour have served as a consultant to VIIV Healthcare and Merck for consultation unrelated to this study.

Author Disclosure Statement

No competing financial interests exist.

References


RATTO-KIM ET AL.


Address correspondence to:
Alexandra Schuetz
Department of Retrovirology
Armed Forces Research Institute of Medical Sciences—United States Component
315/6 Rajvithi Road
Bangkok 10400
Thailand

E-mail: schuetza@hiv-th.org